JP2023520969A5 - - Google Patents

Info

Publication number
JP2023520969A5
JP2023520969A5 JP2022548950A JP2022548950A JP2023520969A5 JP 2023520969 A5 JP2023520969 A5 JP 2023520969A5 JP 2022548950 A JP2022548950 A JP 2022548950A JP 2022548950 A JP2022548950 A JP 2022548950A JP 2023520969 A5 JP2023520969 A5 JP 2023520969A5
Authority
JP
Japan
Prior art keywords
acid sequence
antibody
seq
antibody according
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022548950A
Other languages
English (en)
Japanese (ja)
Other versions
JP7813234B2 (ja
JP2023520969A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/025775 external-priority patent/WO2021207072A1/en
Publication of JP2023520969A publication Critical patent/JP2023520969A/ja
Publication of JP2023520969A5 publication Critical patent/JP2023520969A5/ja
Priority to JP2026013680A priority Critical patent/JP2026089058A/ja
Application granted granted Critical
Publication of JP7813234B2 publication Critical patent/JP7813234B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022548950A 2020-04-07 2021-04-05 抗ｔｍｐｒｓｓ６抗体及びその用途 Active JP7813234B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026013680A JP2026089058A (ja) 2020-04-07 2026-01-29 抗ｔｍｐｒｓｓ６抗体及びその用途

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063006695P 2020-04-07 2020-04-07
US63/006,695 2020-04-07
US202163158265P 2021-03-08 2021-03-08
US63/158,265 2021-03-08
PCT/US2021/025775 WO2021207072A1 (en) 2020-04-07 2021-04-05 Anti-tmprss6 antibodies and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026013680A Division JP2026089058A (ja) 2020-04-07 2026-01-29 抗ｔｍｐｒｓｓ６抗体及びその用途

Publications (3)

Publication Number Publication Date
JP2023520969A JP2023520969A (ja) 2023-05-23
JP2023520969A5 true JP2023520969A5 (enExample) 2024-04-26
JP7813234B2 JP7813234B2 (ja) 2026-02-12

Family

ID=75888147

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022548950A Active JP7813234B2 (ja) 2020-04-07 2021-04-05 抗ｔｍｐｒｓｓ６抗体及びその用途
JP2026013680A Pending JP2026089058A (ja) 2020-04-07 2026-01-29 抗ｔｍｐｒｓｓ６抗体及びその用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026013680A Pending JP2026089058A (ja) 2020-04-07 2026-01-29 抗ｔｍｐｒｓｓ６抗体及びその用途

Country Status (9)

Country Link
US (3) US12215170B2 (enExample)
EP (1) EP4126220A1 (enExample)
JP (2) JP7813234B2 (enExample)
KR (1) KR20230007368A (enExample)
CN (1) CN115243762B (enExample)
AU (1) AU2021251087A1 (enExample)
CA (1) CA3174339A1 (enExample)
TW (1) TW202204422A (enExample)
WO (1) WO2021207072A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021251087A1 (en) 2020-04-07 2022-12-01 Mabwell Therapeutics Inc. Anti-TMPRSS6 antibodies and uses thereof
US20230295345A1 (en) * 2020-04-07 2023-09-21 Mabwell Therapeutics, Inc. Anti-tmprss6 antibodies and uses thereof
WO2022240877A1 (en) 2021-05-11 2022-11-17 Regeneron Pharmaceuticals, Inc. Anti-tmprss6 antibodies and uses thereof
KR20250128393A (ko) * 2022-11-25 2025-08-27 맵웰 테라퓨틱스 인크. 항-tmprss6 항체 및 그의 용도
CN120936629A (zh) * 2023-04-04 2025-11-11 迪斯克医药公司 抗tmprss6抗体及其用途
WO2024211900A1 (en) * 2023-04-06 2024-10-10 Memorial Sloan-Kettering Cancer Center Il-10 receptor antibodies and methods of use thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3614866B2 (ja) 1997-06-12 2005-01-26 リサーチ コーポレイション テクノロジーズ，インコーポレイティド 人工抗体ポリペプチド
WO2005023835A2 (en) 2003-09-09 2005-03-17 Irm Llc Modulators of transmembrane protease serine 6
GB0614201D0 (en) 2006-07-18 2006-08-23 Univ Cardiff Matriptase-2
PE20130588A1 (es) 2007-02-02 2013-05-21 Amgen Inc Hepcidina, antagonistas de la hepcidina y metodos de uso
EP2776564B1 (en) * 2011-11-07 2019-10-02 Ionis Pharmaceuticals, Inc. Modulation of tmprss6 expression
AR093620A1 (es) * 2012-12-17 2015-06-10 Lilly Co Eli Anticuerpos bmp-6
CN106062004A (zh) 2013-12-17 2016-10-26 科马布有限公司 人靶标
WO2016071701A1 (en) * 2014-11-07 2016-05-12 Kymab Limited Treatment of disease using ligand binding to targets of interest
AU2016302768B2 (en) * 2015-07-31 2019-08-22 Medimmune Limited Methods for treating hepcidin-mediated disorders
GB201815629D0 (en) 2018-09-25 2018-11-07 Kymab Ltd Antagonists
EP4065607A1 (en) 2019-11-29 2022-10-05 Kymab Limited Treatment for physiological iron overload
AU2021251087A1 (en) 2020-04-07 2022-12-01 Mabwell Therapeutics Inc. Anti-TMPRSS6 antibodies and uses thereof
CA3216106A1 (en) 2021-04-26 2022-11-03 Alnylam Pharmaceuticals, Inc. Transmembrane protease, serine 6 (tmprss6) irna compositions and methods of use thereof
WO2022229150A1 (en) 2021-04-27 2022-11-03 Silence Therapeutics Gmbh Sirna targeting tmprss6 for the treawtment of myeloproliferative disorders

Similar Documents

Publication Publication Date Title
JP2024038003A5 (enExample)
JP2020508655A5 (enExample)
JP2021530251A5 (enExample)
JP2022512132A5 (enExample)
JP2010502183A5 (enExample)
FI3322727T3 (fi) Humanisoituja tai kimeerisiä CD3-vasta-aineita
JP2018516853A5 (enExample)
JP2021520832A5 (enExample)
JP2012525829A5 (enExample)
HRP20131215T1 (hr) Antagonistiäśka humana monoklonska protutijela specifiäśna za humane slabe epitope
JP2020524510A5 (enExample)
JP2023540526A5 (enExample)
JP2015511817A5 (enExample)
JP2023509390A5 (enExample)
JP2009225799A5 (enExample)
JP2018522888A5 (enExample)
JP2021530244A5 (enExample)
JP2011527899A5 (enExample)
JP2025067915A5 (enExample)
JP2009509538A5 (enExample)
JP2020515277A5 (enExample)
JP2019505477A5 (enExample)
JP2015508056A5 (enExample)
JP2024512135A5 (enExample)
JP2024516098A5 (enExample)